Cernostics Contracts with Geisinger Health Plan to Become an In-network Provider for TissueCypher® Barrett’s Esophagus Assay
08 sept. 2021 09h00 HE
|
Cernostics
Pittsburgh, PA, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cernostics, pioneer of the worlds’ first precision medicine test to predict future development risk of esophageal cancer from Barrett’s esophagus...
Digestive Disease Week® 2021 to Showcase the TissueCypher® Barrett’s Esophagus Assay as a Paradigm-shifting Precision Medicine Tool
17 mai 2021 08h38 HE
|
Cernostics
Pittsburgh, Pennsylvania, May 17, 2021 (GLOBE NEWSWIRE) -- PITTSBURGH, Pennsylvania, May 17, 2021 – Cernostics (https://www.cernostics.com/) a pioneer in delivering spatialomics to the clinic,...
Two Independent Peer-Reviewed Studies Validate Cernostics’ TissueCypher® Barrett’s Esophagus Assay (TissueCypher®) to Accurately Predict Progression to Esophageal Cancer in Patients with Barrett’s Esophagus
18 nov. 2020 09h00 HE
|
Cernostics
Pittsburgh, PA, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Cernostics, Inc. the GI Precision Medicine company, today announced two newly completed clinical studies confirming the ability of the TissueCypher®...
Cernostics Announces Formation of Distinguished Medical Advisory Board Including Top Specialists in All Facets of Esophageal Disease
01 juil. 2019 09h00 HE
|
Cernostics
PITTSBURGH, PA, July 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Cernostics, developer of next-generation cancer diagnostics and prognostics, today announced the formation of a distinguished...
Blinded Independent Validation Study Highlights Effectiveness of Tissue Systems Pathology Test in Predicting Risk of Progression to Esophageal Cancer in Patients with Barrett's Esophagus
21 mai 2019 17h15 HE
|
Cernostics
Data Presented at DDW 2019 Demonstrate Test Potential to Identify Patients Who May Benefit from Increased Surveillance and Early Therapeutic Intervention PITTSBURGH, PA, May 21, 2019 (GLOBE...
Blinded Independent Validation Study of Tissue Systems Pathology Test in Determining Risk of Progression to Esophageal Cancer in Patients with Barrett’s Esophagus to be Presented at DDW 2019
08 mai 2019 09h00 HE
|
Cernostics
PITTSBURGH, May 08, 2019 (GLOBE NEWSWIRE) -- Cernostics, developer of next-generation cancer diagnostics and prognostics today announced that the results of an independent study validating the use...
Cernostics Secures Additional Patents for Proprietary Barrett’s Esophagus Clinical Diagnostics
20 nov. 2018 09h00 HE
|
Cernostics
US and EU patents for TissueCypher® cover methods for detecting risk of progression to esophageal cancer in Barrett’s esophagus patients PITTSBURGH, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Cernostics,...